METHODS: In this retrospective study, 12 Chinese patients with non-acne atrophic scars, including nine with scar erythema, were treated with one to three sessions of 1064 nm FPL treatment. Clinical improvement was objectively assessed through blinded evaluations by external physicians. A modified Manchester Scar Scale (mMSS) and the Clinician Erythema Assessment Scale (CEAS) were individually used to evaluate atrophic scars and scar erythema based on photographs. Physician-assessed and subject-assessed Global Aesthetic Improvement Scale (GAIS) were used to assess changes before and after FPL treatment. Patient satisfaction and adverse events were also documented.
RESULTS: Total mMSS scores, as well as three parameters (color, distortion, and texture), were significantly decreased after FPL treatment, with a mean reduction of 3.18 ± 1.60 in total scores (p < 0.05). The CEAS scores were significantly reduced from 2.41 ± 0.98 before treatment to 0.41 ± 0.40 at the final visit (p < 0.05). Based on physician-assessed and subject-assessed GAIS scores, 11 (91.7%) patients were improved after FPL treatment. 33.3% of patients were very satisfied, and 41.7% were satisfied. No serious, prolonged (> 3 weeks) adverse events were observed.
CONCLUSIONS: Our study suggests that 1064 nm FPL treatment may be a promising option for non-acne atrophic scars, especially with scar erythema. Further studies are needed to confirm our results.
方法:在这项回顾性研究中,12例非痤疮萎缩性疤痕的中国患者,包括9个有疤痕的红斑,用一到三个疗程的1064nmFPL治疗。通过外部医生的盲法评估客观地评估临床改善。根据照片分别使用改良的曼彻斯特疤痕量表(mMSS)和临床医生红斑评估量表(CEAS)来评估萎缩性疤痕和疤痕红斑。医师评估和受试者评估的整体美学改善量表(GAIS)用于评估FPL治疗前后的变化。患者满意度和不良事件也被记录。
结果:mMSS总分,以及三个参数(颜色,失真,和纹理),FPL治疗后显著下降,总分平均减少3.18±1.60(p<0.05)。CEAS评分从治疗前的2.41±0.98显著降低至末次就诊时的0.41±0.40(p<0.05)。根据医生评估和受试者评估的GAIS分数,11例(91.7%)患者经FPL治疗后改善。33.3%的患者非常满意,和41.7%的人感到满意。不认真,观察到延长(>3周)的不良事件。
结论:我们的研究表明,对于非痤疮萎缩性瘢痕,1064nmFPL治疗可能是一个有希望的选择。尤其是有疤痕的红斑.需要进一步的研究来证实我们的结果。